Using Fab- and Ab-based AMs against three different AML target antigens (CD33, CD123, and CLL-1), we demonstrate the specificity and efficacy of AdCAR T cells against AML cell lines and pAML samples in vitro and in vivo. Here, CD33 is linked to acute myeloid leukemia.